Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- TIS -7.6%, (also does not declare dividend), CCRC -2.5%, DISH -1.5%
M&A news:
- GNW -6.4% (Genworth Financial and Oceanwide provide update on CFIUS application)
Other news:
- AEZS -63% (announces that the ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint)
- NTRP -50.8% (top-line results from its Phase 2 study (-202 Study) of Bryostatin-1)
- ITCI -41.4% (FDA has confirmed that the results of Study ITI-007-302 do not preclude them from submitting an NDA based on the efficacy studies they have conducted to date)
- MTNB -5.1% (entered into a Controlled Equity Offering Sales Agreement with Cantor pursuant to the registration statement on Form S-3)
- ANY -3.2% (files for 22,415,550 common share offering by holders)
- SIX -0.5% (to repurchase 5,060,628 shares of common stock from H Partners/affiliated funds at $61.36/share)
Analyst comments:
- WAIR -4.1% (downgraded to Neutral from Buy at Citigroup)
- SSW -3.7% (downgraded to Underperform from Neutral at Credit Suisse)
- WDC -1.5% (downgraded to Hold from Buy at Jefferies)
- SHOP -1.2% (downgraded to Neutral at Monness Crespi & Hardt)